Finkelstein Thompson LLP Announces Investigation of Medco Health Solutions, Inc.

WASHINGTON--(BUSINESS WIRE)--Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Medco Health Solutions, Inc. (“Medco” or the “Company”) (NYSE: MHS) concerning the proposed acquisition of the Company by Express Scripts. Under the terms of the offer, Medco shareholders will receive $28.80 in cash and 0.81 shares of Express Scripts for each share they own. Based on the Company’s closing price on Thursday, the transaction has an implied value of $71.36 per share. The total transaction value is approximately $29.1 billion.

The investigation is focused on the potential unfairness of the consideration to Medco shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among Medco Board members. According to Yahoo! Finance, at least one analyst has set a price target of $77 for the Company’s shares.

If you are interested in discussing your rights as a Medco shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.